与甲胺相关的乳酸性酸症,即使是少量饮酒也会引起:一个病例报告
Yuichi Miyata1, Kiyomitsu Fukaguchi2,3, Hiroshi Koyama2
1Department of Pharmacy, Shonan Kamakura General Hospital, Kamakura, JPN.
Cureus
|November 24, 2025
概括
即使是少量的酒精也可以在2型糖尿病和轻度脏问题患者中引发甲胺相关的乳酸 (MALA). 这一案例凸显了在服用甲福林时,对酒精消费的谨慎需要非常谨慎.
科学领域:
- 内部医学 内部医学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 甲胺是一种常见的第一线治疗2型糖尿病.
- 与甲胺相关的乳酸酸症 (MALA) 是一种罕见但严重的不良反应.
- 马拉的危险因素包括功能障碍,肝功能障碍和过度饮酒.
研究的目的:
- 在患有2型糖尿病和轻度功能障碍的患者中,报告一个因适度饮酒而导致的MALA病例.
- 强调在患有代谢性酸性疾病的患者中考虑MALA的重要性,即使饮酒量有限.
主要方法:
- 一个66岁的男性患有2型糖尿病,正在接受甲福明的病例报告.
- 临床表现,实验室发现 (动脉血气,乳酸水平) 和治疗过程.
- 审查潜在的促成因素,包括酒精消费和功能.
主要成果:
- 患者在饮用大约700毫升酒后出现了严重的乳酸和低血压.
- 怀疑甲胺是病因,患者在停止甲胺和支持性护理后得到改善.
- 患者患有轻度功能障碍,这可能导致了MALA的发展.
结论:
- 适度饮酒可以在2型糖尿病患者和潜在功能障碍患者中加速MALA.
- 医生应建议患者在服用甲福明时饮酒的风险,特别是如果功能受损.
- 早期识别和治疗MALA对于患者的治疗结果至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Hypoglycemia and Glucagon
779
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
779
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K


